title: Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
authors.forename: D P
authors.initials: DP
authors.lastname: Dearnaley
authors.forename: A R
authors.initials: AR
authors.lastname: Norman
authors.forename: M
authors.initials: M
authors.lastname: Shahidi
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D017273:Goserelin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D008297:Male; D020360:Neoadjuvant Therapy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D013739:Testosterone; D016729:Leuprolide